At what enterprise value was GE LIFE SCIENCES acquired in 2019?

During the acquisition of GE LIFE SCIENCES by DANAHER in 2019, the transaction's Enterprise Value is estimated to be in the range of 3b - 100b USD.

What was the EV/EBITDA of GE LIFE SCIENCES when it was acquired by DANAHER?

The estimated EV/EBITDA multiple for GE LIFE SCIENCES is in the range of 15x - 25x.

When was GE LIFE SCIENCES acquired by DANAHER?

GE LIFE SCIENCES was acquired by DANAHER in 2019.

What was the revenue of GE LIFE SCIENCES at the time of the deal?

The revenue of GE LIFE SCIENCES at the time of the deal is estimated to be in the range of 2.5b - 5b USD.

What was the EBITDA of GE LIFE SCIENCES during the acquisition?

GE LIFE SCIENCES's EBITDA is estimated to be in the range of 750M - 1.3b USD.

How is the data for the GE LIFE SCIENCES acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the GE LIFE SCIENCES deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://investors.danaher.com/2019-02-25-Danaher-to-Acquire-the-Biopharma-Business-of-General-Electric-Life-Sciences-for-21-4-Billion

← DATABASE

Home Database Industry & ManufacturingGE LIFE SCIENCES

02/2019

GE LIFE SCIENCES acquired by DANAHER

UNITED STATES Industrial Equipment / Special Machinery / Lab & Scientific Equipment EV 3b - 100b USD

Context

Danaher has finalized an agreement to acquire GE Biopharma in a transformational all-cash transaction, an operation designed to fundamentally redefine the landscape of the global bioprocessing market. The strategic rationale for this transaction centers on a "Bioprocessing-Powerhouse" play, merging the target's industry-leading technical operational depth in chromatography and cell culture with the group’s established life sciences platform and the power of the Danaher Business System. This structural alignment provides the organization with the scientific talent and technological hardware—specifically across upstream and downstream workflows—required to address the surging global demand for biologic drug development.

GE LIFE SCIENCES, which reported an EBITDA margin of in 2019, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Industry & Manufacturing sector (11.8x).

-> Deep-dive in Industry & Manufacturing market trends

Target

GE Biopharma is a USA company specialized in Bioprocessing & Cell Analysis. They have built a distinct space in the healthcare market as the primary provider of the "industrial plumbing" required for the discovery and manufacturing of biologic drugs. Instead of just selling laboratory equipment, they thrive on a philosophy of technical operational depth, providing the essential chromatography hardware, cell culture media, and single-use technologies that allow pharmaceutical companies to scale their innovations. What makes them a go-to partner is their integrated software and consumables model, which ensures that 75% of their revenue is recurring. Their roadmap is centered on enabling the proliferation of complex cell and gene therapies through advanced upstream and downstream processing solutions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2019

2018

Similar deals in Industrial Equipment

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
08/2019	TELEDYNE TECHNOLOGIES INCORPORATED	3M GAS AND FLAME DETECTION	FRANCE	Instrumentation & Measurement
08/2019	AGILENT TECHNOLOGIES	BIOTEK INSTRUMENTS	UNITED STATES	Lab & Scientific Equipment
01/2019	ARDIAN	CELLI GROUP	ITALY	Food & Beverage Lines
12/2018	HITACHI	ABB Power Grids	SWITZERLAND	Electrical Equipment
09/2018	GROUPE ATLANTIC	ACV	BELGIUM	Boilers & Thermal Solutions
07/2018	ARDIAN	COROB	ITALY	Special Machinery
07/2018	WEIR GROUP	ESCO CORPORATION	UNITED STATES	Special Machinery
07/2018	MAREL	MAJA	GERMANY	Food & Beverage Lines
07/2018	TSINGHUA UNIGROUP	LINXENS	FRANCE	Safety & Security
05/2018	MOTION EQUITY PARTNERS	HOLWEG WEBER	UNITED STATES	Robotics & Automation

REFERENCES

Valuation range: EV 3b - 100b USD

Revenue range: 2.5b - 5b USD

EBITDA range: 750M - 1.3b USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of GE LIFE SCIENCES by DANAHER are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: danaher